Latest News: NICE Recommendations on Type 2 Diabetes Treatment and Equity in Care
Summary: The August 2025 issue of the Journal of Diabetes Nursing highlights draft recommendations from NICE that promote more personalised type 2 diabetes management. Key updates include initiating SGLT-2 inhibitors alongside metformin at diagnosis, earlier use of GLP-1 receptor agonists, structured weight-loss follow-up, and a stronger emphasis on reducing health inequities across patient populations.
Key Highlights:
- Personalised treatment: NICE suggests starting SGLT-2 inhibitors with metformin at diagnosis and considering GLP-1 receptor agonists earlier for high-risk groups.
- Reducing inequity: Guidance addresses gaps in prescribing cardio-renal protective therapies, particularly among women, older adults, and minority populations.
- Weight-loss support: Recommends structured support for at least 12 months after weight-management programs or discontinuation of medication.
- Equity strategy: Diabetes UK’s initiative “No One Left Behind: Achieving Equity in Diabetes (2025–2030)” sets out measurable goals to improve access and outcomes.
- Public health impact: Emphasises the long-term cost savings of preventive care and comprehensive obesity management for the healthcare system.
Read the full article in the Journal of Diabetes Nursing
Keywords:
type 2 diabetes,
SGLT-2 inhibitors,
GLP-1 receptor agonists,
weight loss support,
health equity,
Diabetes UK